Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC 415 in Relapsed/Refractory Multiple Myeloma
NCT04649073Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OPC-415 in multiple myeloma (MM), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity and Response rate. Started Feb 2021; status: terminated.
02
Drugs
OPC-415
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04649073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649073.